The Motley Fool

£1k to invest? 2 UK shares I’d buy in an ISA today

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

If you have a lump sum of £1,000, or any other amount to invest, I think it could be sensible to buy UK shares in an ISA. With that in mind, here are two companies I’ve got my eye on today. 

UK shares to buy

Hikma Pharmaceuticals (LSE: HIK) has been one of the best-performing stocks on the London market this year. Investor sentiment towards the pharmaceutical group has improved because it supplies several of the drugs required to treat coronavirus

5 Stocks For Trying To Build Wealth After 50

Markets around the world are reeling from the coronavirus pandemic… and with so many great companies trading at what look to be ‘discount-bin’ prices, now could be the time for savvy investors to snap up some potential bargains.

But whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be a daunting prospect during such unprecedented times.

Fortunately, The Motley Fool UK analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global upheaval…

We’re sharing the names in a special FREE investing report that you can download today. And if you’re 50 or over, we believe these stocks could be a great fit for any well-diversified portfolio.

Click here to claim your free copy now!

Thanks for the growing demand for these drugs, City analysts are expecting the company to report earnings per share for the year of $1.70. That’s up from $1.50 at the beginning of the year. 

There are other reasons why I think Hikma could be one of the best UK shares to buy today. The demand for healthcare around the world is only growing, and the company is one of the largest producers of low-cost generic treatments.

For emerging and developing economies, these low-cost products are vital. As such, Hikma has a very defensive nature and is likely to continue to produce steady returns for investors for many decades to come. 

Over the past five-years, Hikma’s bottom line has doubled, thanks to the growing demand for pharmaceutical products around the world. The company’s own research and development efforts have helped improve growth. With profits surging, Hikma has become a dividend champion. Its payout has grown at a compound annual rate of 17% since 2014. Today, the stock supports a dividend yield of 1.5%.

In my opinion, this income potential, as well as the company’s long-term growth outlook, is highly exciting. These qualities are relatively unique among UK shares. 

Rentokil Initial

Pest control business Rentokil Initial (LSE: RTO) has achieved a similar rate of growth to Hikma over the past five years. The company’s long-term outlook is also extremely attractive.

The company is potentially one of the best-known pest control businesses in the UK. Demand for its services is only growing. Scientists believe climate change is contributing to rising pest levels. That’s terrible news for the planet, but potentially good news for pest control businesses.

On top of this organic growth, Rentokil has a strong track record of buying up smaller competitors and integrating them into the wider business. As the company grows, it looks as if this trend will continue. The pest control market is large but highly fragmented. Rentokil is one of the few businesses that has the size and skill to acquire smaller competitors

As such, I think it may be worth acquiring the stock as part of an ISA portfolio of UK shares. The company has significant growth potential in the years ahead, which could lead to large total returns for investors. Even if the stock does look expensive at current levels, I think it’s a price worth paying to buy this UK growth champion.

One Killer Stock For The Cybersecurity Surge

Cybersecurity is surging, with experts predicting that the cybersecurity market will reach US$366 billion by 2028more than double what it is today!

And with that kind of growth, this North American company stands to be the biggest winner.

Because their patented “self-repairing” technology is changing the cybersecurity landscape as we know it…

We think it has the potential to become the next famous tech success story.

In fact, we think it could become as big… or even BIGGER than Shopify.

Click here to see how you can uncover the name of this North American stock that’s taking over Silicon Valley, one device at a time…

Rupert Hargreaves owns no share mentioned. The Motley Fool UK has recommended Hikma Pharmaceuticals. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.